A Phase 2 interventional study of ABBV-3373 and Placebo for ABBV-3373 in Rheumatoid Arthritis (RA), sponsored by AbbVie. Completed at 30 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-19.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 71st largest by enrollment, is one of 4 that started in 2019, is one of 9 in phase 2, and was the 78th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
80 studies in Arthritis, Rheumatoid by AbbVie: 5 open now, 6 under way, 1 of them phase 3. Of 71 finished, 54 (76%) have results posted.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 33rd largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2019, is one of 16 in phase 2, and was the 65th registered.
AbbVie’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 80 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety, tolerability, and efficacy of ABBV-3373 in participants with moderately to severely active rheumatoid arthritis (RA) on background methotrexate (MTX) compared with adalimumab.
This study consists of a 12-week double-blind active-controlled phase and a 12 week double-blind extension period.
In the active-controlled period of the first 12 weeks of treatment, participants are randomized to receive either ABBV-3373 100 mg intravenously (IV) every other week (EOW) or adalimumab 80 mg subcutaneously (SC) EOW according to a 2:1 ratio.
At Week 12, the administration of ABBV-3373 was to stop to assess the durability of the observed clinical effects up to 24 weeks. Participants randomized to ABBV-3373 were to receive placebo injections, whereas participants randomized into the adalimumab arm were to continue their 80 mg dosing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will be administered with 100 mg ABBV-3373 by intravenous infusion and placebo to adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive placebo to adalimumab every other week until Week 22.
Drug: ABBV-3373 · Drug: Placebo for adalimumab
Participants will be administered with placebo to ABBV-3373 by intravenous infusion and 80 mg adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive 80 mg adalimumab subcutaneously every other week until Week 22.
Drug: Placebo for ABBV-3373 · Drug: Adalimumab
ABBV-3373 is administered as intravenous (IV) infusion
Placebo for ABBV-3373 is administered as IV infusion
Adalimumab is administered as subcutaneous (SC) injection
Also known as: Humira
Placebo for adalimumab is administered as subcutaneous (SC) injection
Change From Baseline to Week 12 in Disease Activity Score (DAS) 28 (C-reactive Protein [CRP])
The DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (measured on a visual analog scale \[VAS\] from 0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 (CRP) range from 0.96 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in Clinical Disease Activity Index (CDAI)
The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of tender joint count (out of 28 evaluated joints) and swollen joint count (out of 28 evaluated joints), Patient Global Assessment of Disease Activity and Physician Global Assessment of Disease Activity both measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 76 with higher scores indicating higher disease activity. A negative change from Baseline indicates improvement in disease activity.
Time frame: Baseline and Week 12
Change From Baseline in Simplified Disease Activity Index (SDAI)
The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28-joint assessment), Patient Global Assessment of Disease Activity and Physician Global Assessment of Disease Activity both measured on a VAS from 0-10 cm and level of CRP (in mg/dL; normal \< 1 mg/dL). The SDAI has a range from 0 to 86, with higher scores indicating higher disease activity. A negative change from Baseline indicates improvement in disease activity.
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in DAS28 (Erythrocyte Sedimentation Rate [ESR])
The DAS28 (ESR) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (measured on a VAS from 0-100 mm), and ESR (in mm/hr). Scores on the DAS28 (ESR) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline indicates improvement in disease activity.
Time frame: Baseline and Week 12
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28 (CRP) at Week 12
The DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (measured on a VAS from 0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 (CRP) range from 0.96 to approximately 10, where higher scores indicate more disease activity. A DAS28 (CRP) score less than or equal to 3.2 indicates low disease activity.
Time frame: Week 12
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Participants with moderately to severely active rheumatoid arthritis (RA) on background methotrexate (MTX) were enrolled at 14 sites in the United States and Puerto Rico, Poland, Hungary, and Israel.
| Milestone | Adalimumab | ABBV-3373 Followed by Placebo |
|---|---|---|
| Started | 17 | 31 |
| Completed | 17 | 31 |
| Not completed | 0 | 0 |
| Milestone | Adalimumab | ABBV-3373 Followed by Placebo |
|---|---|---|
| Started | 17 | 31 |
| Completed | 15 | 30 |
| Not completed | 2 | 1 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
The DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (measured on a visual analog scale \[VAS\] from 0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 (CRP) range from 0.96 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.
| score on a scale | Adalimumab | ABBV-3373 |
|---|---|---|
| Change From Baseline to Week 12 in Disease Activity Score (DAS) 28 (C-reactive Protein [CRP]) | -2.51 ± 0.293 | -2.65 ± 0.215 |
The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of tender joint count (out of 28 evaluated joints) and swollen joint count (out of 28 evaluated joints), Patient Global Assessment of Disease Activity and Physician Global Assessment of Disease Activity both measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 76 with higher scores indicating higher disease activity. A negative change from Baseline indicates improvement in disease activity.
| score on a scale | Adalimumab | ABBV-3373 |
|---|---|---|
| Change From Baseline to Week 12 in Clinical Disease Activity Index (CDAI) | -26.30 ± 2.656 | -27.99 ± 1.955 |
The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28-joint assessment), Patient Global Assessment of Disease Activity and Physician Global Assessment of Disease Activity both measured on a VAS from 0-10 cm and level of CRP (in mg/dL; normal \< 1 mg/dL). The SDAI has a range from 0 to 86, with higher scores indicating higher disease activity. A negative change from Baseline indicates improvement in disease activity.
| score on a scale | Adalimumab | ABBV-3373 |
|---|---|---|
| Change From Baseline in Simplified Disease Activity Index (SDAI) | -27.42 ± 2.659 | -28.50 ± 1.961 |
The DAS28 (ESR) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (measured on a VAS from 0-100 mm), and ESR (in mm/hr). Scores on the DAS28 (ESR) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline indicates improvement in disease activity.
| score on a scale | Adalimumab | ABBV-3373 |
|---|---|---|
| Change From Baseline to Week 12 in DAS28 (Erythrocyte Sedimentation Rate [ESR]) | -2.55 ± 0.344 | -2.76 ± 0.254 |
The DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (measured on a VAS from 0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 (CRP) range from 0.96 to approximately 10, where higher scores indicate more disease activity. A DAS28 (CRP) score less than or equal to 3.2 indicates low disease activity.
| percentage of participants | Adalimumab | ABBV-3373 |
|---|---|---|
| Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28 (CRP) at Week 12 | 58.8 (39.2 to 78.5) | 54.8 (40.1 to 69.5) |
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Adalimumab | ABBV-3373 |
|---|---|---|
| Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | 64.7 (45.6 to 83.8) | 51.6 (36.8 to 66.4) |
Collected over From first dose of study drug up to 70 days after last dose; the treatment duration was 12 weeks in each period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: ABBV-3373 | 0/31 (0%) | 4/31 (12.9%) | 4/31 (12.9%) |
| Period 1: Adalimumab | 0/17 (0%) | 0/17 (0%) | 12/17 (70.6%) |
| Period 2: ABBV-3773 / Placebo | 0/30 (0%) | 0/30 (0%) | 7/30 (23.3%) |
| Period 2: Adalimumab / Adalimumab | 0/16 (0%) | 2/16 (12.5%) | 12/16 (75%) |
| Event | Period 1: ABBV-3373 | Period 1: Adalimumab | Period 2: ABBV-3773 / Placebo | Period 2: Adalimumab / Adalimumab |
|---|---|---|---|---|
| BREAST ABSCESSInfections and infestations | 0/31 | 0/17 | 0/30 | 1/16 |
| BRONCHITISInfections and infestations | 0/31 | 0/17 | 0/30 | 1/16 |
| NON-CARDIAC CHEST PAINGeneral disorders | 1/31 | 0/17 | 0/30 | 0/16 |
| ANAPHYLACTIC SHOCKImmune system disorders | 1/31 | 0/17 | 0/30 | 0/16 |
| PNEUMONIAInfections and infestations | 1/31 | 0/17 | 0/30 | 0/16 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/31 | 0/17 | 0/30 | 0/16 |
| Event | Period 1: ABBV-3373 | Period 1: Adalimumab | Period 2: ABBV-3773 / Placebo | Period 2: Adalimumab / Adalimumab |
|---|---|---|---|---|
| NASOPHARYNGITISInfections and infestations | 0/31 | 1/17 | 3/30 | 2/16 |
| URINARY TRACT INFECTIONInfections and infestations | 2/31 | 2/17 | 1/30 | 1/16 |
| RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders | 0/31 | 0/17 | 3/30 | 0/16 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 0/31 | 0/17 | 2/30 | 1/16 |
| HEADACHENervous system disorders | 2/31 | 1/17 | 0/30 | 1/16 |
| LEUKOPENIABlood and lymphatic system disorders | 0/31 | 0/17 | 0/30 | 1/16 |
| PERIORBITAL SWELLINGEye disorders | 0/31 | 0/17 | 0/30 | 1/16 |
| MOUTH SWELLINGGastrointestinal disorders | 0/31 | 0/17 | 0/30 | 1/16 |
| NAUSEAGastrointestinal disorders | 0/31 | 0/17 | 0/30 | 1/16 |
| INJECTION SITE PRURITUSGeneral disorders | 0/31 | 0/17 | 0/30 | 1/16 |
The Full Analysis Set (FAS) includes all randomized participants who received at least 1 dose of the study drugs.
| Age, Continuous(years) | Adalimumab | ABBV-3373 Followed by Placebo | Total |
|---|---|---|---|
| Mean | 54.0 ± 10.21 | 52.8 ± 13.14 | 53.2 ± 12.08 |
| Age, Customized(Participants) | Adalimumab | ABBV-3373 Followed by Placebo | Total |
|---|---|---|---|
| < 40 years | 0 | 5 | 5 |
| 40 to 65 years | 13 | 21 | 34 |
| ≥ 65 years | 4 | 5 | 9 |
| Sex: Female, Male(Participants) | Adalimumab | ABBV-3373 Followed by Placebo | Total |
|---|---|---|---|
| Female | 14 | 24 | 38 |
| Male | 3 | 7 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Adalimumab | ABBV-3373 Followed by Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 8 | 11 |
| Not Hispanic or Latino | 14 | 23 | 37 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Adalimumab | ABBV-3373 Followed by Placebo | Total |
|---|---|---|---|
| White | 16 | 28 | 44 |
| Black | 1 | 2 | 3 |
| Other | 0 | 1 | 1 |
| Duration of RA Symptoms(years) | Adalimumab | ABBV-3373 Followed by Placebo | Total |
|---|---|---|---|
| Mean | 5.9 ± 3.22 | 8.0 ± 8.73 | 7.2 ± 7.29 |
| Duration of RA Diagnosis(years) | Adalimumab | ABBV-3373 Followed by Placebo | Total |
|---|---|---|---|
| Mean | 3.5 ± 3.09 | 5.0 ± 6.02 | 4.5 ± 5.19 |
| Baseline Use of Systemic Glucocorticoids(Participants) | Adalimumab | ABBV-3373 Followed by Placebo | Total |
|---|---|---|---|
| Yes | 5 | 11 | 16 |
| No | 12 | 20 | 32 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Mar 2019 to primary completion in Apr 2020, 12 months.
Results were first posted in Jul 2021, 1 year 3 months after primary completion. A results delay was requested in Mar 2021.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 12 months is below that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab